Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:CINCNASDAQ:NUVLNYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.21+1.9%$30.62$22.90▼$36.45$5.15B0.511.77 million shs725,911 shsCINCCinCor Pharma$29.06-0.5%$29.08$10.53▼$43.15$1.27BN/A818,447 shs6.35 million shsNUVLNuvalent$71.000.0%$71.48$55.54▼$113.51$5.08B1.42488,236 shs407,857 shsPBHPrestige Consumer Healthcare$87.11+2.0%$83.17$62.35▼$90.04$4.32B0.44296,450 shs382,537 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.71%+0.84%+11.18%-14.94%+25.03%CINCCinCor Pharma0.00%0.00%0.00%0.00%0.00%NUVLNuvalent-0.56%+6.59%+1.46%-12.27%+4.41%PBHPrestige Consumer Healthcare-1.28%+5.64%+4.51%+0.17%+20.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.2505 of 5 stars3.41.00.04.23.11.71.9CINCCinCor PharmaN/AN/AN/AN/AN/AN/AN/AN/ANUVLNuvalent2.6414 of 5 stars3.52.00.00.03.53.30.0PBHPrestige Consumer Healthcare3.7336 of 5 stars1.33.01.73.52.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.75Moderate Buy$38.3322.82% UpsideCINCCinCor Pharma 0.00N/AN/AN/ANUVLNuvalent 2.90Moderate Buy$115.5062.68% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.337.14% UpsideCurrent Analyst Ratings BreakdownLatest CINC, NUVL, ALKS, and PBH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.004/28/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/27/2025ALKSAlkermesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $52.003/21/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.003/14/2025NUVLNuvalentUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$100.00 ➝ $100.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.40$2.34 per share13.32$9.05 per share3.45CINCCinCor PharmaN/AN/AN/AN/A($1.74) per shareN/ANUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/APBHPrestige Consumer Healthcare$1.14B3.79$5.12 per share17.03$36.10 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.3822.782.2023.57%30.80%19.09%7/23/2025 (Estimated)CINCCinCor Pharma-$50.37M-$17.28N/AN/AN/AN/A-33.03%-27.21%N/ANUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%N/APBHPrestige Consumer Healthcare$209.34M$4.2920.4018.302.6919.13%12.36%6.39%N/ALatest CINC, NUVL, ALKS, and PBH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million2/27/2025Q4 2024NUVLNuvalent-$1.03-$1.05-$0.02-$1.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACINCCinCor PharmaN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.18%N/A44.29%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65CINCCinCor PharmaN/A51.9651.96NUVLNuvalentN/A23.0723.07PBHPrestige Consumer Healthcare0.563.682.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CINCCinCor Pharma99.15%NUVLNuvalent97.26%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%CINCCinCor Pharma15.60%NUVLNuvalent12.52%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableCINCCinCor Pharma1543.76 million36.94 millionNot OptionableNUVLNuvalent4071.60 million62.16 millionOptionablePBHPrestige Consumer Healthcare54049.54 million48.75 millionOptionableCINC, NUVL, ALKS, and PBH HeadlinesRecent News About These CompaniesPBH vs. ESLOY: Which Stock Should Value Investors Buy Now?May 14 at 12:45 PM | zacks.comPrestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin IncreaseMay 13 at 4:52 PM | finance.yahoo.comEquities Analysts Set Expectations for PBH Q1 EarningsMay 13 at 3:45 AM | americanbankingnews.comSusquehanna International Group LLP Increases Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 13 at 3:39 AM | marketbeat.comQ1 Earnings Forecast for PBH Issued By William BlairMay 13 at 3:32 AM | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Posts Earnings Results, Beats Expectations By $0.02 EPSMay 12 at 11:36 PM | marketbeat.comBNP Paribas Financial Markets Purchases 186,524 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)May 12 at 4:25 AM | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Upgraded to "Hold" at Royal Bank of CanadaMay 11, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comPrestige Consumer Healthcare (NYSE:PBH) Upgraded by Royal Bank of Canada to "Hold" RatingMay 11, 2025 | americanbankingnews.comPrestige Consumer Healthcare (NYSE:PBH) Issues FY 2026 Earnings GuidanceMay 10, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of "Moderate Buy" by AnalystsMay 10, 2025 | marketbeat.comPrestige Consumer Healthcare Inc (PBH) Q4 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comPrestige Consumer Healthcare Inc (PBH) Q4 2025 Earnings Call Highlights: Record Revenue and ...May 9, 2025 | finance.yahoo.comNorthern Trust Corp Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 9, 2025 | marketbeat.comPrestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue EstimatesMay 8, 2025 | zacks.comUPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and EarningsMay 8, 2025 | globenewswire.comPrestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and EarningsMay 8, 2025 | globenewswire.comTudor Investment Corp ET AL Acquires Shares of 16,836 Prestige Consumer Healthcare Inc. (NYSE:PBH)May 8, 2025 | marketbeat.comInsights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key MetricsMay 7, 2025 | msn.comAristotle Capital Boston LLC Sells 64,071 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCINC, NUVL, ALKS, and PBH Company DescriptionsAlkermes NASDAQ:ALKS$31.21 +0.59 (+1.93%) As of 04:00 PM EasternAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.CinCor Pharma NASDAQ:CINCCinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Nuvalent NASDAQ:NUVL$71.00 -0.02 (-0.03%) As of 04:00 PM EasternNuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Prestige Consumer Healthcare NYSE:PBH$87.11 +1.71 (+2.00%) As of 03:59 PM EasternPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
